Bavarian Nordic A/S · OMXCOP:BAVA

Bavarian Nordic A/S — Bavarian Nordic R/I — Q3 2026 Earnings Presentation

27 slides from Bavarian Nordic A/S's earnings presentation, Nov 13, 2026

  1. Slide 1: 9M 2026 Interim report

    9M 2026 Interim report for the nine-month period ending September 30, 2026 Bavarian Nordic A/S, Philip Heymans Allé 3, DK-2900 Hellerup, Denmark Company Registration No. 16271187

  2. Slide 2: Key highlights in the third quarter

    Management’s review Financial statements Notes Key highlights in the third quarter Financial highlights Full-year guidance maintained Strong performance provides a solid foundation → Revenue in the third quarter was DKK 1,805 million, compared to → The upgraded full-year guidance for 2026, issued on

  3. Slide 3: A strong momentum for Bavarian Nordic's next chapter

    Management’s review Financial statements Notes A strong momentum for Bavarian Nordic’s next chapter I am delighted to have joined Bavarian Nordic as President and • How do we fully capture the growth potential in Travel CEO at an exciting point in the company’s development. Health, including rabies

  4. Slide 4: Performance snapshot

    Management’s review Financial statements Notes Performance snapshot Revenue EBITDA margin Contents Revenue (Q3) Revenue (9M) EBITDA margin (Q3) EBITDA margin (9M) → Key figures and ratios 5 1,805 mDKK ▲1% 4,897 mDKK ▲2% 34% 35% → Performance 6 → Product revenue overview 7 → Financial review 8 Travel

  5. Slide 5: Key figures and ratios

    Management’s review Financial statements Notes Key figures and ratios DKK thousand Q3 2026 Q3 2025 9M 2026 9M 2025 FY 2025 DKK thousand Q3 2026 Q3 2025 9M 2026 9M 2025 FY 2025 Income statements Financial Ratios1 Revenue 1,804,918 1,794,910 4,897,166 4,793,003 6,243,956 Gross margin 51.9% 49.8% 54.0%

  6. Slide 6: Performance

    Management’s review Financial statements Notes Performance Travel Health Rabipur/RabAvert Encepur Vimkunya Vivotif Rabipur/RabAvert revenue grew by 39% in the Encepur revenue increased by 9% in the first nine Vimkunya revenue was DKK 151 million in the Vivotif revenue in the first nine months grew b

  7. Slide 7: Public Preparedness and Product revenue overview

    Management’s review Financial statements Notes Public Preparedness Product revenue overview JYNNEOS/IMVANEX/IMVAMUNE FX + FX + Revenue from JYNNEOS/IMVANEX/IMVAMUNE Organic inorganic Reported Organic inorganic Reported was DKK 1,875 million in the first nine months, a DKK million Q3 2026 Q3 2025 gro

  8. Slide 8: Financial review

    Management’s review Financial statements Notes Financial review Financial statements for the period January 1 – unusually high in the third quarter amounting to Research and development costs Financial items September 30, 2026 are un-audited. Comparison DKK 259 million (DKK 210 million) and this was

  9. Slide 9: Cash flow, equity and risks

    Management’s review Financial statements Notes to DKK 750 million was launched. As of September 501 million) with main drivers being payment of 30, 2026, DKK 113 million of the first tranche of the completion milestone to GSK and the share DKK 250 million was repurchased. buy-back program. Cash flow

  10. Slide 10: Outlook for 2026

    Management’s review Financial statements Notes Outlook for 2026 Full-year guidance maintained 2026 revenue and EBITDA margin expectations Assumptions The Travel Health revenue guidance includes DKK The financial guidance for 2026, upgraded on 200 million from the sale of Vimkunya. Current Updated Up

  11. Slide 11: Products and pipeline

    Management’s review Financial statements Notes Products and pipeline Travel Health Public Preparedness Other pipeline updates Commercial products Vimkunya® JYNNEOS®/IMVANEX®/IMVAMUNE® (MVA-BN®) EBV Travel Health Chikungunya vaccine. Mpox and smallpox vaccine An Investigational New Drug (IND) applica

  12. Slide 12: Shareholder information

    Management’s review Financial statements Notes Shareholder information Share capital Financial calendar 2027 Share price development, 9M In September, 28,590 new shares were issued The dates for the annual and quarterly reports and Indexed upon exercise of warrants by employees. There the annual gen

  13. Slide 13: Consolidated condensed financial statements

    Management’s review Financial statements Notes Consolidated condensed financial statements Statements Notes Note 1 Material accounting policies 20 Income statement 14 Note 2 Key accounting estimates, assumptions and uncertainties 20 Note 3 Revenue 20 Statement of comprehensive income 14 Note 4 Produ

  14. Slide 14: Consolidated income statement and comprehensive income

    Management’s review Financial statements Notes Consolidated income statement Consolidated statement of comprehensive income DKK thousand Note Q3 2026 Q3 2025 9M 2026 9M 2025 FY 2025 DKK thousand Q3 2026 Q3 2025 9M 2026 9M 2025 FY 2025 Revenue 3 1,804,918 1,794,910 4,897,166 4,793,003 6,243,956 Net p

  15. Slide 15: Consolidated statement of cash flow

    Management’s review Financial statements Notes Consolidated statement of cash flow DKK thousand 9M 2026 9M 2025 FY 2025 DKK thousand 9M 2026 9M 2025 FY 2025 Investments in product rights (1) (1,104,537) (1,105,244) Net profit for the period 1,195,518 1,674,175 1,375,378 Investments in other intangib

  16. Slide 16: Consolidated statement of financial position: Assets

    Management’s review Financial statements Notes Consolidated statement of financial position Assets DKK thousand Note 9M 2026 9M 2025 FY 2025 DKK thousand Note 9M 2026 9M 2025 FY 2025 Assets Inventories 8 2,573,706 2,517,453 2,513,919 Product rights 5,313,255 5,667,388 5,570,541 Developed production

  17. Slide 17: Consolidated statement of financial position: Equity and liabilities

    Management’s review Financial statements Notes Consolidated statement of financial position Equity and liabilities DKK thousand Note 9M 2026 9M 2025 FY 2025 DKK thousand Note 9M 2026 9M 2025 FY 2025 Equity and liabilities Debt to credit institutions 2,169 2,143 2,147 Share capital 792,653 792,367 79

  18. Slide 18: Consolidated statement of changes in equity

    Management’s review Financial statements Notes Consolidated statement of changes in equity Reserves for Reserves for fair value of Treasury Retained currency financial Share-based DKK thousand Share capital shares earnings adjustment instruments payment Equity Equity as of January 1, 2026 792,367 (9

  19. Slide 19: Consolidated statement of changes in equity

    Management’s review Financial statements Notes Consolidated statement of changes in equity Reserves for Reserves for fair value of Treasury Retained currency financial Share-based DKK thousand Share capital shares earnings adjustment instruments payment Equity Equity as of January 1, 2025 788,548 (2

  20. Slide 20: Notes: Accounting policies and Revenue

    Management’s review Financial statements Notes Notes Note 1 Note 3 Material accounting policies Revenue The interim financial statements are prepared in accordance with IAS 34, Interim Financial Reporting, as adopted by EU and the additional Danish requirements for submission of interim reports for

  21. Slide 21: Notes 4-7: Costs and financial items

    Management’s review Financial statements Notes Note 4 Note 6 Production costs Financial income DKK thousand Q3 2026 Q3 2025 9M 2026 9M 2025 FY 2025 DKK thousand Q3 2026 Q3 2025 9M 2026 9M 2025 FY 2025 Cost of goods sold 474,047 549,118 1,379,229 1,451,738 1,869,858 Financial income from bank and dep

  22. Slide 22: Notes 8, 10, 11

    Management’s review Financial statements Notes Note 8 Note 10 Inventories Other receivables DKK thousand 9M 2026 9M 2025 FY 2025 DKK thousand 9M 2026 9M 2025 FY 2025 Raw materials and supply materials 315,650 230,530 262,296 Receivable VAT and duties 26,485 13,590 40,525 Work in progress 1,859,147 1

  23. Slide 23: Note 12 Financial instruments

    Management’s review Financial statements Notes Note 12 Financial instruments Fair value hierarchy for financial instruments measured at fair value As of September 30, 2026 As of December 31, 2025 DKK thousand Level 1 Level 2 Total Level 1 Level 2 Total Securities 1,835,250 - 1,835,250 1,619,004 - 1,

  24. Slide 24: Note 13 Warrants

    Management’s review Financial statements Notes Note 13 Warrants Outstanding warrants as of September 30, 2026 Outstanding as Warrants Outstanding as of of January 1 Additions exercised Annulled Terminated Transferred September 30 Corporate Management 428,277 - - - - - 428,277 Other Executive Managem

  25. Slide 25: Notes 14-16 Contingent liabilities and subsequent events

    Management’s review Financial statements Notes Note 14 Significant changes in contingent liabilities and other contractual obligations No significant changes in contingent liabilities and other contractual obligations have occurred since December 31, 2025. Note 15 Significant events after the balanc

  26. Slide 26: Management's statement

    Management’s review Financial statements Notes Management’s statement The Board of Directors and Corporate Management Copenhagen, November 13, 2026 today reviewed and approved the Bavarian Nordic A/S interim report for the period January 1 to September 30, 2026. Corporate Management The interim repo

  27. Slide 27: Bavarian Nordic A/S contact and about us

    Bavarian Nordic A/S About us Philip Heymans Allé 3 Bavarian Nordic is a leading global provider of travel vaccines and a preferred partner with governments and DK-2900 Hellerup international organizations on delivering vaccines for improving public preparedness, such as mpox/smallpox Denmark vaccine

Bavarian Nordic R/I — Q3 2026 Earnings Presentation on 6ix